#1 Clinical Trials Search in Europe

Inaxaplin

Inaxaplin (IXP) is currently undergoing clinical trials to evaluate its effectiveness and safety in treating proteinuric APOL1-mediated kidney disease (AMKD). This Phase 2b open-label study aims to assess the drug’s impact on patients with AMKD, including those with additional health conditions such as type 2 diabetes, sickle cell disease, HIV, or lupus nephritis. The trial focuses on measuring changes in urine protein levels and monitoring potential side effects over a 13-week treatment period.

Table of Contents

What is INAXAPLIN?

INAXAPLIN, also known as VX-147, is a new medication being developed to treat APOL1-mediated Proteinuric Kidney Disease (AMKD). It is currently undergoing clinical trials to evaluate its effectiveness and safety.[1] INAXAPLIN is taken orally as a film-coated tablet and is being studied in both adults and children with AMKD.

What is APOL1-mediated Proteinuric Kidney Disease (AMKD)?

APOL1-mediated Proteinuric Kidney Disease is a genetic condition that affects the kidneys. It is caused by specific variations in the APOL1 gene, which can lead to kidney damage and loss of kidney function over time. The term “proteinuric” means that people with this condition have high levels of protein in their urine, which is a sign of kidney damage.[1]

How INAXAPLIN Works

While the exact mechanism of action is not detailed in the provided information, INAXAPLIN is designed to target the underlying cause of AMKD. By addressing the effects of the APOL1 gene variations, it aims to reduce protein in the urine and slow down the progression of kidney disease.[1]

Clinical Trial Details

The clinical trial for INAXAPLIN is a Phase 2/3 study, which means it is in an advanced stage of testing. Here are some key points about the trial:

  • It is a double-blind, placebo-controlled study, which helps ensure reliable results.
  • The trial aims to evaluate both the effectiveness and safety of INAXAPLIN.
  • It includes both adult and pediatric patients with AMKD.
  • The study will last for at least 48 weeks, with some participants being followed for up to 2 years.[1]

Eligibility Criteria

To participate in the INAXAPLIN trial, patients must meet certain criteria. Some of the key eligibility requirements include:

  • Having a specific APOL1 genotype (G1/G1, G2/G2, or G1/G2)
  • Being between 12 and 65 years old (18 to 65 for the initial phase)
  • Having a certain level of protein in the urine and reduced kidney function
  • Not having other underlying causes of kidney disease or diabetes
  • Meeting specific health and laboratory criteria[1]

Potential Benefits

The main goals of the INAXAPLIN treatment are:

  1. To reduce the amount of protein in the urine, which is measured as a percentage change in UPCR (Urine Protein to Creatinine Ratio). This is important because high levels of protein in the urine are a sign of kidney damage.
  2. To slow down the decline in kidney function, which is measured by the eGFR (estimated Glomerular Filtration Rate) slope. A slower decline in eGFR means the kidneys are losing function more slowly.
  3. To decrease the risk of serious kidney-related events, such as:
    • A significant decline in kidney function
    • The need for dialysis or kidney transplant
    • Reaching a very low level of kidney function

These potential benefits could significantly improve the quality of life and long-term health outcomes for people with AMKD.[1]

Safety Considerations

As with any new medication, safety is a crucial aspect of the INAXAPLIN trial. The researchers are carefully monitoring:

  • Any side effects or adverse events reported by participants
  • Changes in laboratory test results
  • Effects on heart rhythm (through ECG monitoring)
  • Changes in vital signs

The trial also excludes people with certain health conditions or risk factors to ensure participant safety. It’s important to note that the full safety profile of INAXAPLIN will only be known after the completion of this and potentially other clinical trials.[1]

Aspect Details
Drug Name Inaxaplin (IXP, VX-147)
Trial Phase Phase 2b
Study Type Open-label
Target Condition Proteinuric APOL1-mediated kidney disease (AMKD)
Treatment Duration 13 weeks
Primary Outcome Percent change in Urine Albumin-Creatinine Ratio (UACR)
Secondary Outcome Safety and tolerability assessment
Included Comorbidities Type 2 diabetes, sickle cell disease, HIV, lupus nephritis
Administration Oral tablets, once daily

FAQ

  • What is Inaxaplin? Inaxaplin (IXP), also known as VX-147, is a drug being tested for the treatment of proteinuric APOL1-mediated kidney disease (AMKD). It is administered as tablets for oral use.
  • What is the main purpose of this clinical trial? The main purpose of this Phase 2b clinical trial is to evaluate the efficacy, safety, and tolerability of Inaxaplin in participants with proteinuric APOL1-mediated kidney disease (AMKD).
  • How long does the treatment last in this trial? In this trial, participants receive a single dose of Inaxaplin once daily for a period of 13 weeks.
  • What is the primary outcome being measured in this study? The primary outcome being measured is the percent change in Urine Albumin-Creatinine Ratio (UACR) from baseline to Week 13 of treatment.
  • Are participants with other health conditions included in this trial? Yes, the trial includes participants with AMKD who may also have one of the following conditions: Type 2 diabetes mellitus, sickle cell disease, HIV, or lupus nephritis.

Ongoing Clinical Trials on Inaxaplin

  • Study on the Effects of Inaxaplin for Adults and Children with APOL1-mediated Proteinuric Kidney Disease

    Recruiting

    4 1
    Investigated drugs:
    Belgium France

Glossary

  • APOL1-mediated kidney disease (AMKD): A type of kidney disease caused by specific variations in the APOL1 gene, which can lead to proteinuria and kidney damage.
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney damage or disease.
  • Urine Albumin-Creatinine Ratio (UACR): A test that measures the amount of albumin (a protein) in the urine compared to creatinine, used to assess kidney function and damage.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being given.
  • Phase 2b trial: A stage of clinical research that further evaluates the effectiveness and safety of a drug in a larger group of patients.
  • Efficacy: The ability of a drug or treatment to produce the desired effect or outcome.
  • Adverse Events (AEs): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.
  • Serious Adverse Events (SAEs): Adverse events that result in death, are life-threatening, require hospitalization, or cause significant disability.
  • Comorbidities: The presence of one or more additional health conditions or diseases alongside a primary condition.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-inaxaplin-for-adults-and-children-with-apol1-mediated-proteinuric-kidney-disease/